金陵药业(000919) - 2022 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2022 was ¥701,676,933.27, representing a year-on-year increase of 1.87%[5]. - Net profit attributable to shareholders for the same period was ¥33,735,225.06, a significant increase of 56.47% compared to the previous year[5]. - The basic earnings per share for Q3 2022 was ¥0.0661, up by 54.47% year-on-year[5]. - Total operating revenue for the current period is ¥2,053,856,118.01, a decrease of 2.7% from ¥2,111,013,131.98 in the previous period[23]. - Net profit for the current period is ¥105,406,239.67, a decrease of 14.0% compared to ¥122,756,762.52 in the previous period[24]. - Basic and diluted earnings per share for the current period are both ¥0.1826, down from ¥0.1935 in the previous period[25]. - Total comprehensive income for the current period is ¥119,568,574.16, slightly down from ¥122,756,762.52 in the previous period[25]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥4,558,330,945.72, reflecting a 2.49% increase from the end of the previous year[5]. - As of September 30, 2022, the total assets of Jinling Pharmaceutical Co., Ltd. amounted to CNY 4,558,330,945.72, an increase from CNY 4,447,665,260.23 at the beginning of the year[21]. - The company's current assets totaled CNY 2,395,433,878.20, compared to CNY 2,288,834,000.04 at the start of the year, reflecting a growth of approximately 4.65%[20]. - The total liabilities stood at CNY 909,166,026.93, slightly down from CNY 913,096,006.32 at the beginning of the year[21]. - The equity attributable to shareholders of the parent company increased to CNY 3,007,413,799.43 from CNY 2,927,728,885.61, marking an increase of about 2.72%[21]. Cash Flow - The company's cash flow from operating activities decreased by 32.74% year-on-year, totaling ¥141,229,553.92[5][13]. - The net cash flow from operating activities for Q3 2022 was ¥141,229,553.92, a decrease of 32.8% compared to ¥209,965,324.74 in Q3 2021[27]. - The total cash and cash equivalents at the end of Q3 2022 stood at ¥1,122,269,631.54, an increase from ¥1,020,710,012.97 in Q3 2021[27]. - The company reported a total cash outflow from operating activities of ¥1,925,915,764.21, which is an increase from ¥1,879,745,650.11 in Q3 2021[27]. - Cash inflow from financing activities totaled ¥29,272,880.00, up from ¥15,000,000.00 in Q3 2021[27]. - The net cash flow from financing activities was -¥46,078,805.56, compared to -¥38,031,678.88 in the previous year[27]. Expenses and Income - The company's goodwill increased by 72.59% due to the acquisition of a 65.00% stake in Chizhou Dongsheng Pharmaceutical Co., Ltd.[9]. - Non-operating income for the year increased by 147.86% due to higher government subsidies received[11]. - Investment income decreased by 54.02% year-on-year, primarily due to the absence of performance compensation from subsidiaries[12]. - The company reported a 36.00% decrease in income tax expenses compared to the previous year, attributed to a reduction in taxable income[13]. - Research and development expenses increased to ¥45,168,326.22, up 14.5% from ¥39,351,727.41 in the previous period[24]. - Cash received from sales of goods and services is ¥2,041,251,922.89, a decrease of 1.0% from ¥2,061,084,625.63 in the previous period[26]. - Other income for the current period is ¥7,781,011.80, an increase from ¥3,139,232.80 in the previous period[24]. - Investment income for the current period is ¥10,752,550.99, down from ¥23,385,821.36 in the previous period[24]. Inventory and Receivables - Accounts receivable increased to CNY 409,019,830.84 from CNY 320,639,675.01, representing a rise of about 27.5%[20]. - The company reported a decrease in inventory to CNY 226,891,654.63 from CNY 245,476,356.41, a reduction of approximately 7.5%[20]. Other Information - The company has not reported any new product launches or technological advancements in this quarter[20]. - There are no significant updates regarding market expansion or mergers and acquisitions mentioned in the report[20]. - The company continues to utilize idle funds for wealth management products, as indicated in previous announcements[17].